Interpretive discrepancies caused by target values inter‐batch variations in chemiluminescence immunoassay for SARS‐CoV‐2 IgM/IgG by MAGLUMI

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00209805%3A_____%2F21%3A00078471" target="_blank" >RIV/00209805:_____/21:00078471 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00159816:_____/20:00073377 RIV/65269705:_____/21:00074236

Výsledek na webu

<a href="https://onlinelibrary.wiley.com/doi/epdf/10.1002/jmv.26612" target="_blank" >https://onlinelibrary.wiley.com/doi/epdf/10.1002/jmv.26612</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1002/jmv.26612" target="_blank" >10.1002/jmv.26612</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Interpretive discrepancies caused by target values inter‐batch variations in chemiluminescence immunoassay for SARS‐CoV‐2 IgM/IgG by MAGLUMI

Popis výsledku v původním jazyce

Plasma specimens from coronavirus disease 2019 patients were double-tested for anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies by two different batches of MAGLUMI 2019-nCov immunoglobulin M/immunoglobulinG (IgM/IgG) assays to evaluate IgM/IgG levels, qualitative interpretation, antibody kinetics, and linearity of diluted specimen. Here we show that (i) high-level IgM specimens need to be diluted with negative human plasma but not kit diluents and(ii) measured anti-SARS-CoV-2 IgM/IgG concentrations are substantially higher with later marketed immunoassay batch leading to (iii) the change of qualitative interpretation (positive vs. negative) in 12.3% of specimens measured for IgM, (iv) the informative time-course pattern of antibody production only when data from different immunoassay batches are not combined.

Název v anglickém jazyce

Interpretive discrepancies caused by target values inter‐batch variations in chemiluminescence immunoassay for SARS‐CoV‐2 IgM/IgG by MAGLUMI

Popis výsledku anglicky

Plasma specimens from coronavirus disease 2019 patients were double-tested for anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies by two different batches of MAGLUMI 2019-nCov immunoglobulin M/immunoglobulinG (IgM/IgG) assays to evaluate IgM/IgG levels, qualitative interpretation, antibody kinetics, and linearity of diluted specimen. Here we show that (i) high-level IgM specimens need to be diluted with negative human plasma but not kit diluents and(ii) measured anti-SARS-CoV-2 IgM/IgG concentrations are substantially higher with later marketed immunoassay batch leading to (iii) the change of qualitative interpretation (positive vs. negative) in 12.3% of specimens measured for IgM, (iv) the informative time-course pattern of antibody production only when data from different immunoassay batches are not combined.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30102 - Immunology

Projekt

<a href="/cs/project/LM2018125" target="_blank" >LM2018125: Banka klinických vzorků</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2021

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Journal of medical virology

ISSN

0146-6615

e-ISSN

—

Svazek periodika

93

Číslo periodika v rámci svazku

3

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

5

Strana od-do

1805-1809

Kód UT WoS článku

000583206600001

EID výsledku v databázi Scopus

2-s2.0-85094640715